Cargando…
Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues
To investigate whether IL-21 levels predict treatment outcomes of salvage therapy among patients with suboptimal response (SOR) to nucleos(t)ide analogues (NAs), serum IL-21 levels were measured in a prospective cohort of hepatitis B e antigen (HBeAg)-positive patients with SOR to antiviral therapy....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818553/ https://www.ncbi.nlm.nih.gov/pubmed/33500704 http://dx.doi.org/10.3892/etm.2021.9648 |
_version_ | 1783638859308859392 |
---|---|
author | Li, Yue Pan, Calvin Q. Ji, Shibo Yan, Gaiqin Cheng, Jun Liu, Shunai Xing, Huichun |
author_facet | Li, Yue Pan, Calvin Q. Ji, Shibo Yan, Gaiqin Cheng, Jun Liu, Shunai Xing, Huichun |
author_sort | Li, Yue |
collection | PubMed |
description | To investigate whether IL-21 levels predict treatment outcomes of salvage therapy among patients with suboptimal response (SOR) to nucleos(t)ide analogues (NAs), serum IL-21 levels were measured in a prospective cohort of hepatitis B e antigen (HBeAg)-positive patients with SOR to antiviral therapy. The patients switched therapy to entecavir (ETV) with or without adefovir (ADV) for 104 weeks. IL-21 levels at treatment week 12 in patients who achieved HBeAg loss with undetectable levels of hepatitis B virus (HBV)-DNA at week 104 were the primary endpoint and the results were compared with those of corresponding patients without such an endpoint. Furthermore, IL-21 levels at treatment week 12 in patients who achieved an HBeAg-level decline at week 104 were assessed as the secondary endpoint. Among 24 enrolled patients with SOR to ADV (n=21), telbivudine (n=2) or ETV (n=1), the median (10-90th percentile) levels of HBeAg, HBV-DNA and ALT at baseline were 2.7 (0.2-3.1) log(10) S/CO, 5.2 (3.5-7.5) log(10) IU/ml and 0.9 (0.5-3.1) upper limit of normal, respectively. Comparison of the patients with and without HBeAg loss at week 104 indicated that their mean IL-21 levels did not significantly differ at week 12 (63.0±14.4 vs. 55.9±10.5 pg/ml; P=0.26). In the secondary endpoint analyses of patients with and without HBeAg level decline, the elevated levels of IL-21 at the first 12 weeks were significantly higher in the decline group (15.6±8.3 vs. 3.1±13.2 pg/ml; P=0.03). Following adjustment for confounding factors, the elevated levels of IL-21 from baseline to week 12 independently predicted an HBeAg level decline at week 104 (odds ratio=1.137, R(2)=0.23; P=0.047). In conclusion, the serum IL-21 levels at the first 12 weeks during the salvage therapy independently predicted HBeAg level decline at treatment week 104 in patients with SOR to NAs (ClinicalTrials.gov identifier: NCT01829685; date of registration, April 2013). |
format | Online Article Text |
id | pubmed-7818553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-78185532021-01-25 Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues Li, Yue Pan, Calvin Q. Ji, Shibo Yan, Gaiqin Cheng, Jun Liu, Shunai Xing, Huichun Exp Ther Med Articles To investigate whether IL-21 levels predict treatment outcomes of salvage therapy among patients with suboptimal response (SOR) to nucleos(t)ide analogues (NAs), serum IL-21 levels were measured in a prospective cohort of hepatitis B e antigen (HBeAg)-positive patients with SOR to antiviral therapy. The patients switched therapy to entecavir (ETV) with or without adefovir (ADV) for 104 weeks. IL-21 levels at treatment week 12 in patients who achieved HBeAg loss with undetectable levels of hepatitis B virus (HBV)-DNA at week 104 were the primary endpoint and the results were compared with those of corresponding patients without such an endpoint. Furthermore, IL-21 levels at treatment week 12 in patients who achieved an HBeAg-level decline at week 104 were assessed as the secondary endpoint. Among 24 enrolled patients with SOR to ADV (n=21), telbivudine (n=2) or ETV (n=1), the median (10-90th percentile) levels of HBeAg, HBV-DNA and ALT at baseline were 2.7 (0.2-3.1) log(10) S/CO, 5.2 (3.5-7.5) log(10) IU/ml and 0.9 (0.5-3.1) upper limit of normal, respectively. Comparison of the patients with and without HBeAg loss at week 104 indicated that their mean IL-21 levels did not significantly differ at week 12 (63.0±14.4 vs. 55.9±10.5 pg/ml; P=0.26). In the secondary endpoint analyses of patients with and without HBeAg level decline, the elevated levels of IL-21 at the first 12 weeks were significantly higher in the decline group (15.6±8.3 vs. 3.1±13.2 pg/ml; P=0.03). Following adjustment for confounding factors, the elevated levels of IL-21 from baseline to week 12 independently predicted an HBeAg level decline at week 104 (odds ratio=1.137, R(2)=0.23; P=0.047). In conclusion, the serum IL-21 levels at the first 12 weeks during the salvage therapy independently predicted HBeAg level decline at treatment week 104 in patients with SOR to NAs (ClinicalTrials.gov identifier: NCT01829685; date of registration, April 2013). D.A. Spandidos 2021-03 2021-01-15 /pmc/articles/PMC7818553/ /pubmed/33500704 http://dx.doi.org/10.3892/etm.2021.9648 Text en Copyright: © Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Li, Yue Pan, Calvin Q. Ji, Shibo Yan, Gaiqin Cheng, Jun Liu, Shunai Xing, Huichun Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues |
title | Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues |
title_full | Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues |
title_fullStr | Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues |
title_full_unstemmed | Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues |
title_short | Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues |
title_sort | serum il-21 levels predict hbeag decline during rescue therapy in patients with partial response to nucleos(t)ide analogues |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818553/ https://www.ncbi.nlm.nih.gov/pubmed/33500704 http://dx.doi.org/10.3892/etm.2021.9648 |
work_keys_str_mv | AT liyue serumil21levelspredicthbeagdeclineduringrescuetherapyinpatientswithpartialresponsetonucleostideanalogues AT pancalvinq serumil21levelspredicthbeagdeclineduringrescuetherapyinpatientswithpartialresponsetonucleostideanalogues AT jishibo serumil21levelspredicthbeagdeclineduringrescuetherapyinpatientswithpartialresponsetonucleostideanalogues AT yangaiqin serumil21levelspredicthbeagdeclineduringrescuetherapyinpatientswithpartialresponsetonucleostideanalogues AT chengjun serumil21levelspredicthbeagdeclineduringrescuetherapyinpatientswithpartialresponsetonucleostideanalogues AT liushunai serumil21levelspredicthbeagdeclineduringrescuetherapyinpatientswithpartialresponsetonucleostideanalogues AT xinghuichun serumil21levelspredicthbeagdeclineduringrescuetherapyinpatientswithpartialresponsetonucleostideanalogues |